Gain insights like never before by using ctDNA testing with unparalleled sensitivity
For clinicians
Haystack MRD™ is the most sensitive minimal residual disease (MRD) test available, so you can have the best information to make treatment management decisions that lead to favorable patient outcomes. Our unmatched test performance delivers the best clinical information when answering patients’ 2 most pressing post-surgery questions:
Did my treatment work?
Go beyond standard risk assessment for adjuvant chemotherapy guidance to ensure the right treatment for the right person at the right time.
Do I need additional therapy?
Why test for ctDNA?
Circulating tumor DNA (ctDNA) detection is a noninvasive method to assess tumor burden with a blood sample. Recent data also correlate ctDNA levels in postsurgical cancer patients with recurrence-free survival (RFS) and risk of recurrence.
3-yr RFS*
3-yr RFS*
more likely to recur
*Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. doi:10.1126/scitranslmed.aaf6219
Haystack MRD™ is a tumor-informed, liquid biopsy test that begins with tumor whole-exome sequencing (WES) to identify patient-specific somatic mutations. A personalized MRD test is then developed to detect ctDNA, which indicates the presence of residual, recurrent, or resistant disease.
Haystack MRD is purpose-built for ultra-sensitive ctDNA detection in patients with solid tumors and can be used to detect residual disease to guide adjuvant therapy, to monitor treatment response, and for recurrence surveillance.
DYNAMIC is the first interventional, random-controlled trial to demonstrate a significant clinical benefit to utilizing MRD testing to guide adjuvant therapy in early-stage solid tumor patients. Powered by a highly optimized version of the technology employed in DYNAMIC, Haystack MRD is rooted in demonstrated clinical care.
Proven MRD test superiority
This unique ability delivers unparalleled sensitivity, with successful detection down to 1 part per million (PPM; or, 0.0001% tumor fraction), which translates to fewer false-negatives to ensure patients who need treatment receive it, with greater lead time between molecular and clinical recurrence.
With an error rate that is >100x lower than other solid tumor MRD tests, the cutoff for MRD detection can be set much lower, dramatically improving sensitivity.
Better sensitivity means molecular recurrence can be detected at lower levels and with greater lead time in advance of clinical recurrence compared to other methods.
With an error rate that is 100x lower than other solid tumor MRD tests, Haystack MRD delivers greater confidence in ctDNA test results.
